Score outperforms current NCCN guidelines for MM patients receiving immunomodulatory therapy
FRIDAY, Aug. 16, 2019 (HealthDay News) — For patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs), a risk assessment model, SAVED, can predict the risk for venous thromboembolism (VTE), according to a study published in the July issue of the Journal of the National Comprehensive Cancer Network.
Ang Li, M.D., from the University of Washington School of Medicine in Seattle, and colleagues selected 2,397 patients from the Surveillance, Epidemiology, and End Result-Medicare database with newly diagnosed MM receiving IMiDs to derive a risk assessment model. The model was validated externally using data from the Veterans Health Administration database (1,251 participants).
The final model, which was named the SAVED score, included previous surgery, Asian race, VTE history, age ≥80 years, and dexamethasone dose. The researchers found that the model stratified about 30 percent of patients as high-risk in both the derivation and validation cohorts. For high-risk versus low-risk groups in the derivation and validation cohorts, the hazard ratios were 1.85 and 1.98, respectively (both P < 0.01). In contrast, for the stratification method recommended in the current National Comprehensive Cancer Network (NCCN) Guidelines for Cancer-Associated Venous Thromboembolic Disease, the hazard ratios were 1.21 (P = 0.17) and 1.41 (P = 0.07) for the corresponding risk groups.
“We are hopeful that this clinical tool will aid informed shared decision making between providers and patients with MM regarding VTE risk before IMiD initiation,” the authors write.
Two authors disclosed financial ties to the pharmaceutical industry.
Copyright © 2019 HealthDay. All rights reserved.
